Asieris Pharmaceuticals Reports Over RMB 200M Revenue in 2024 with Strong Competitive Growth in Women's Health and Oncology#China#Shanghai#oncology#Asieris_Pharma#APL-1702
Asieris Pharmaceuticals Reports Over RMB 200M Revenue in 2024 with Strong Competitive Growth in Women's Health and Oncology
Asieris Pharmaceuticals has announced its 2024 Annual Report, showcasing a remarkable revenue growth exceeding RMB 200 million, fueled by innovative products and strategic expansion.
third-news.com
April 18, 2025 at 2:20 PM
Asieris Pharmaceuticals Reports Over RMB 200M Revenue in 2024 with Strong Competitive Growth in Women's Health and Oncology#China#Shanghai#oncology#Asieris_Pharma#APL-1702